Cardiovascular Disease and Chronic Kidney Disease

Chronic Renal Disease

Volumn , Issue , 2015, Pages 181-198

  Parfrey, Patrick S ^a   Barrett, Brendan J ^a  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

Author keywords

Arteriosclerosis; Atherosclerosis; Cardiomyopathy; Cardiovascular disease; Cardiovascular risk factors; Chronic kidney disease; Congestive heart failure; Ischemic heart disease; Left ventricular hypertrophy; Sudden cardiac death

Indexed keywords

EID: 84945986498     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-411602-3.00016-0     Document Type: Chapter

References (136)

1. Foley RN, Murray AM, Li S, McBean AM, Eggers PW, Collins AJ Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the Unites States Medicare population, 1998 to 1999. J Am Soc Nephrol 2005, 16(2):489-495.
2. Mitsnefes MM Cardiovascular disease in children with chronic kidney disease. J Am Soc Nephrol 2012, 23(4):578-585.
3. Ninomiya T, Perkovic V, de Galan BE, Zoungas S, Pillai A, Jardine M, et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 2009, 20(8):1813-1821.
4. Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, et al. Chronic Kidney Disease Prognosis Consortium. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010, 375(9731):2073-2081.
5. Hemmelgarn BR, Manns BJ, Lloyd A, James MT, Klarenbach S, Quinn RR, et al. Relation between kidney function, proteinuria and adverse outcomes. JAMA 2010, 303(5):423-429.
6. Tonelli M, Muntner P, Lloyd A, Manns BJ, Klarenbach S, Pannu N, et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet 2012, 380(9844):807-814.
7. Waheed S, Matsushita K, Sang Y, Hoogeveen R, Ballantyne C, Coresh J, et al. Combined association of albuminuria and cystatin-C based estimated GFR with mortality, coronary artery disease, and heart failure outcomes: The Atherosclerosis Risk in Communities (ARIC) study. Am J Kid Dis 2012, 60(2):207-216.
8. Deo R, Sotoodehnia N, Katz R, Sarnak MJ, Fried LF, Chonchol M, et al. Cystatin C and sudden cardiac death risk in the elderly. Circ Cardiovasc Qual Outcomes 2010, 3(2):159-164.
9. Shilpak MG, Katz R, Kestenbaum B, Siscovick D, Fried L, Newman A, et al. Rapid decline of kidney function increases cardiovascular risk in the elderly. J Am Soc Nephrol 2009, 20(12):2625-2630.
10. Wright RS, Reeder GS, Herzog CA, Albright RC, Williams BA, Dvorak DL, et al. Acute myocardial infarction and renal dysfunction: a high-risk combination. Ann Intern Med 2002, 137(7):563-570.
11. Fox CS, Muntner P, Chen AY, Alexander KP, Roe MT, Cannon CP, et al. Use of evidence based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST- segment elevation myocardial infarction in patients with chronic kidney disease: a report from national Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network Registry. Circulation 2010, 121(3):357-365.
12. Shlipak MG, Smith CL, Rathore SS, Massie BM, Krumholz HM Renal function, digoxin therapy, and heart failure outcomes: evidence from the digoxin intervention group trial. J Am Soc Nephrol 2004, 15(8):2195.
13. Pun PH, Smarz TR, Honeycutt ER, Shaw LK, Al-Khatib SM, Middleton JP Chronic kidney disease is associated with increased risk of sudden cardiac death among patients with coronary artery disease. Kidney Int 2009, 76(6):652-658.
14. Goldenberg I, Moss AJ, McNitt S, Zareba W, Andrews ML, Hall WJ, et al. Relations among renal function, risk of sudden cardiac death, and benefit of the implanted cardiac defibrillator in patients with ischemic left ventricular dysfunction. Am J Cardiol 2006, 98(4):485-490.
15. Park M, Hsu C-Y, Yong-mei L, Keane M, Rosas SE, Dries D, et al. Associations between kidney function and subclinical cardiac abnormalities in CKD. J Am Soc Nephrol 2012, 23(10):1725-1734.
16. Eckardt KU, Scherhag A, Macdougall IC, Tsakiris D, Clyne N, Locatelli F, et al. Left ventricular geometry predicts cardiovascular outcomes associated with anemia correction in CKD. J Am Soc Nephrol 2009, 20(12):2651-2660.
17. Kramer H, Toto R, Peshock R, Cooper R, Victor R Association between chronic kidney disease and coronary artery calcification: The Dallas Heart Study. J Am Soc Nephrol 2005, 16(2):507-513.
18. Kestenbaum BR, Adeney KL, de Boer IH, Ix JH, Shlipak MG, Siscovick DS Incidence and progression of coronary calcification in chronic kidney disease: the Multi-Ethnic Study of Atherosclerosis. Kidney Int 2009, 76(9):991-998.
19. Leskinen Y, Paana T, Saha H, Groundstroem K, Lehtimäki T, Kilpinen S, et al. Valvular calcification and its relationship to atherosclerosis in chronic kidney disease. J Heart Valve Dis 2009, 18(4):429-438.
20. Rostand RG, Kirk KA, Rutsky EA Dialysis ischemic heart disease: insights from coronary arteriography. Kidney Int 1984, 25(4):653-659.
21. Muntner P, He J, Astor BC, Folsom AR, Coresh J Traditional and non-traditional risk factors predict coronary heart disease in chronic kidney disease: results from the Atherosclerosis Risk in Communities Study. J Am Soc Nephrol 2005, 16(2):529-538.
22. Strobel NA, Fassett RG, Marsh SA, Coombs JS Oxidative stress biomarkers as predictors of cardiovascular disease. Int J Cardiol 2011, 147(2):191-201.
23. Bostom AG, Culleton BF Hyperhomocysteinemia in chronic renal disease. J Am Soc Nephrol 1999, 10(4):891-896.
24. London GM, Marchais SJ, Guerin AP, Boutouyrie P, Métivier F, de Vernejoul MC Associations of bone activity, calcium load, aortic stiffness and calcifications in ESRD. J Am Soc Nephrol 2008, 19(9):1827-1835.
25. Abedini S, Meinitzer A, Holme I, März W, Weihrauch G, Fellstrøm B, et al. Asymmetrical dimethylarginine is associated with renal and cardiovascular outcomes and all-cause mortality in renal transplant recipients. Kidney Int 2010, 77(1):44-50.
26. Coll B, Rodrigues JA, Craver L, Orbe J, Martínez-Alonso M, Ortiz A, et al. Serum levels of metalloproteinase-10 are associated with the severity of atherosclerosis in patients with chronic kidney disease. Kidney Int 2010, 78(12):1275-1280.
27. Baber U, Stone GW, Weisg G, Moreno P, Dangas G, Maehara A, et al. Coronary plaque composition, morphology, and outcomes in patients with and without chronic kidney disease presenting with acute coronary syndrome. JACC Cardiovasc Imaging 2012, 5(3 Suppl.):553-561.
28. Pelisek T, Assadian A, Sarkar O, Eckstein HH, Frank H Carotid plaque composition in chronic kidney disease: a retrospective analysis of patients undergoing carotid endarterectomy. Eur J Vasc Endovasc Surg 2010, 39(1):11-16.
29. Yilmaz MI, Qureshi AR, Carrero JJ, Saglam M, Suliman ME, Caglar K, et al. Predictors of carotid artery intima-media thickness in chronic kidney disease and kidney transplant patients without overt cardiovascular disease. Am J Nephrol 2010, 31(3):214-221.
30. Brady TM, Schneider MF, Flynn JT, Cox C, Samuels J, Saland J, et al. Carotid intima-media thickness in children with CKD: results from the CKiD study. Clin J Am Soc Nephrol 2012, 7(12):1930-1937.
31. Erbel R, Ge J, Bockisch A, Kearney P, Görge G, Haude M, et al. Value of intracoronary ultrasound and Doppler in the differentiation of angiographically normal coronary arteries: a prospective study in patients with angina pectoris. Eur Heart J 1996, 17(6):880-889.
32. Zoneraich S Unrevelling the conundrums of the diabetic heart diagnosed in 1876: prelude to genetics. Can J Cardiol 1994, 10(9):945-950.
33. Amann K, Wiest G, Zimmer G, Gretz N, Ritz E, Mall G Reduced capillary density in the myocardium of uremic rats - a stereological study. Kidney Int 1992, 42(5):1079.
34. Raine AE, Seymour AM, Roberts AF, Radda GK, Ledingham JG Impairment of cardiac function and energetics in experimental renal failure. J Clin Invest 1993, 92(6):2934-2940.
35. Massry SG, Smogorzewski M Mechanisms through which parathyroid hormone mediated its deleterious effects on organ function in uremia. Semin Nephrol 1994, 14(3):219-231.
36. London GM, Marchais SJ, Guerin AP, Metivier F, Pannier B Cardiac hypertrophy and arterial alterations in end-stage renal disease: hemodynamic factors. Kidney Int Suppl 1993, 41:S42-S49.
37. Carrero JJ, Kyriazis J, Sonmez A, Tzanakis I, Qureshi AR, Stenvinkel P, et al. Prolactin levels, endothelial dysfunction, and the risk of cardiovascular events in patients with CKD. Clin J Am Soc Nephrol 2012, 7(2):207-215.
38. Moe SM, Chen NX Mechanisms of vascular calcification in chronic kidney disease. J Am Soc Nephrol 2008, 19(2):213-216.
39. Kavousi M, Elias-Smale S, Rutten JH, Leening MJ, Vliegenthart R, Verwoert GC, et al. Evaluation of newer risk markers for coronary heart disease risk classification: a cohort study. Ann Intern Med 2012, 156(6):438-444.
40. Amann K Media calcification and intima calcification are distinct entities in chronic kidney disease. Clin J Am Soc Nephrol 2008, 3(6):1599-1605.
41. McCullough PA, Agrawal V, Danielewicz E, Abela GS Accelerated atherosclerotic calcification and Monckeberg's sclerosis: a continuum of advanced vascular pathology in chronic kidney disease. Clin J Am Soc Nephrol 2008, 3(6):1585-1598.
42. Chiu YW, Adler SG, Budoff MJ, Takasu J, Ashai J, Mehrotra R Coronary artery calcification and mortality in diabetic patients with proteinuria. Kidney Int 2010, 77(12):1107-1114.
43. Nakamura S, Ishibashi-Ueda H, Zizuma S, Yoshihara F, Horio T, Kawano Y Coronary artery calcification in patients with chronic kidney disease and coronary artery disease. Clin J Am Soc Nephrol 2009, 4(12):1892-1990.
44. Hassan NA, D'Orsi ET, D'Orsi CJ, O'Neill WC The risk for medial arterial calcification in CKD. Clin J Am Soc Nephrol 2012, 7(2):275-279.
45. Temmar M, Liabeuf S, Renard C, Czernichow S, Esper NE, Shahapuni I, et al. Pulse wave velocity and vascular calcification at different stages of chronic kidney disease. J Hypertens 2010, 28(1):163-169.
46. Grossman W Cardiac hypertrophy: useful adaptation or pathologic process?. Am J Med 1980, 69:576.
47. London GM, Drueke TB Atherosclerosis and arteriosclerosis in chronic renal failure. Kidney Int 1997, 51(6):1678.
48. London GM, Pannier B, Marchais SJ, Guerin AP Calcification of the aortic valve in the dialyzed patient. J Am Soc Nephrol 2000, 11(4):778-783.
49. Siedlecki AM, Kin X, Muslin AJ Uremic cardiac hypertrophy is reversed by rapamycin but not by lowering of blood pressure. Kidney Int 2009, 75(8):800-808.
50. Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, et al. FGF-23 induces left ventricular hypertrophy. J Clin Invest 2011, 121(11):4393-4408.
51. Kendrick J, Cheung AK, Kaufman JJ, Greene T, Roberts WL, Smits G, et al. FGF-23 associated with death, cardiovascular events and initiation of chronic dialysis. J Am Soc Nephrol 2011, 22(10):1913-1922.
52. Thadhani R, Appelbaum E, Pritchett Y, Chang Y, Wenger J, Tamez H, et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA 2012, 307(7):674-684.
53. Katz AM The cardiomyopathy of overload: an unnatural growth response in the hypertrophied heart. Ann Intern Med 1994, 121(5):363-371.
54. Otto CM, Lind BK, Kitzman DW, Gersh BJ, Siscovick DS Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly. N Engl J Med 1999, 341(3):142-147.
55. Masuda C, Dohi K, Sakurai Y, Fukuda H, Fujii S, Sugimoto T, et al. Impact of chronic kidney disease in the presence and severity of aortic stenosis in patients at high risk for coronary artery disease. Cardiovascular Ultrasound 2011, 16(9):31.
56. Hillege HL, Girbes AR, de Kam PJ, Boomsma F, de Zeeuw D, Charlesworth A, et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 2000, 102(2):203-210.
57. Ananthapanyasut W, Napan S, Rudolph EH, Harindhanavudhi T, Ayash H, Guglielmi KE, et al. Prevalence of atrial fibrillation and its predictors in nondialysis patients with chronic kidney disease. Clin J Am Soc Nephrol 2010, 5(2):173-181.
58. Johansson M, Gao SA, Friberg P, Annerstedt M, Bergström G, Carlström J, et al. Elevated temporal QT variability index in patients with chronic renal failure. Clin Sci (Lond) 2004, 107(6):583-588.
59. Johansson M, Gao SA, Fribert P, Annerstedt M, Bergström G, Carlström J, et al. Reduced baroreflex effectiveness index in hypertensive patients with chronic renal failure. Am J Hypertens 2005, 18(7):995-1000.
60. de Bruyne MC, Hoes AW, Kors JA, Hofman A, van Bemmel JH, Grobbee DE QTc dispersion predicts cardiac mortality in the elderly: the Rotterdam Study. Circulation 1998, 97(5):467-472.
61. Eagle KA, Berger PB, Calkins H, Chaitman BR, Ewy GA, Fleischmann KE, et al. ACC/AHA guideline update for perioperative cardiovascular evaluation for noncardiac surgery: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). Circulation 2002, 105(10):1257-1267.
62. Li D, Jiala I, Keffer J Greater frequency of increased cardiac troponin T than increased cardiac troponin I in patients with chronic renal failure. Clin Chem 1996, 42(1):114.
63. McCullough PA, Nowak RM, Foreback C, Tokarski G, Tomlanovich MC, Khoury NE, et al. Performance of multiple cardiac biomarkers measured in the emergency department in patients with chronic kidney disease and chest pain. Acad Emerg Med 2002, 9(12):1389-1396.
64. Freda BJ, Tang WH, Van Lente F, Peacock WF, Francis GS Cardiac troponins in renal insufficiency: review and clinical implications. J Am Coll Cardiol 2002, 40(12):2065-2071.
65. Coley CM, Eagle KA Preoperative assessment and perioperative management of cardiac ischemic risk in noncardiac surgery. Curr Probl Cardiol 1996, 21(5):289-382.
66. Le A, Wilson R, Douek K, Pulliam L, Tolzman D, Norman D, et al. Prospective risk stratification in renal transplant candidates for cardiac death. Am J Kidney Dis 1994, 24(1):65-71.
67. Rabbat CG, Treleaven DJ, Russell JD, Ludwin D, Cook DJ Prognostic value of myocardial perfusion studies in patients with end-stage renal disease assessed for kidney or kidney-pancreas transplantation: a meta-analysis. J Am Soc Nephrol 2003, 14:431-439.
68. Chertow GM, Burke SK, Raggi P, Treat to Goal Working Group Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002, 62(1):245-252.
69. Raggi P, Chertow GM, Torres PU, Csiky B, Naso A, Nossuli K, et al. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant 2011, 26(4):1327-1339.
70. Weustink AC, Mollet NR, Neefjes LA, Meijboom WB, Galema TW, van Mieghem CA, et al. Diagnostic accuracy and clinical utility of noninvasive testing for coronary artery disease. Ann Intern Med 2010, 152(10):630-639.
71. Barrett BJ, Parfrey PS Clinical practice: preventing nephrotoxicity induced by contrast medium. N Engl J Med 2006, 354(4):379-386.
72. ACT Investigators Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography: Main results from the randomized Acetylcysteine for contrast-induced nephropathy trial (ACT). Circulation 2011, 124(11):1250-1259.
73. DeLoach SS, Townsend RR Vascular stiffness; its management and significance for epidemiologic and outcome studies. Clin J Am Soc Nephrol 2008, 3(1):184-192.
74. Karohl C, Gascon LD, Raggi P Noninvasive imaging for assessment of calcification in chronic kidney disease. Nat Rev Nephrol 2011, 7(10):567-577.
75. Pombo JF, Troy BL, Russell RO Left ventricular volumes and ejection fraction by echocardiography. Circulation 1971, 43(4):480-490.
76. Levy D, Savage DD, Garrison RJ, Anderson KM, Kannel WB, Castelli WP, et al. Echocardiographic criteria for left ventricular hypertrophy: the Framingham Heart Study. Am J Cardiol 1987, 59(9):956-960.
77. FHN Trial Group, Chertow GM, Levin NW, Beck GJ, Depner TA, Eggers PW, et al. In-center hemodialysis six times per week versus three times per week. N Engl J Med 2010, 363(24):2287-2300.
78. [accessed 22.01.2013]. http://www.kdigo.org/clinical_practice:guidelines/pdf/KDIGO_BP_GL.pdf.
79. Lewis JB Blood pressure control in chronic kidney disease: is less really more?. J Am Soc Nephrol 2010, 21(7):1086-1092.
80. Heart Outcomes Prevention Evaluation Study Investigators.Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000;355(9200): 253-9.
81. Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, Irbesartan Diabetic Nephropathy Trial Collaborative Study Group, et al. Cardiovascular outcomes in the irbesartan diabetic nephropathy trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med 2003, 138(7):542-549.
82. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345(12):861-869.
83. Perkovic V, Ninomiya T, Arima H, Gallagher M, Jardine M, Cass A, et al. Chronic kidney disease, cardiovascular events, and the effects of perindopril-based blood pressure lowering: data from the PROGRESS study. J Am Soc Nephrol 2007, 18(10):2766-2772.
84. Tobe SW, Clase CM, Gao P, McQueen M, Grosshennig A, Wang X, et al. Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies. Circulation 2011, 123(10):1098-1107.
85. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, ALTITUDE Investigators, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012, 367(23):2204-2213.
86. Kim-Mitsuyama S, Ogawa H, Matsui K, Jinnouchi T, Jinnouchi H, Arakawa K, et al. An angiotensin II receptor blockade-calcium channel blocker combination prevents cardiovascular events in elderly high-risk hypertensive patients with chronic kidney disease better than high-dose angiotensin II receptor blockade alone. Kidney Int 2012, 83(1):167-176.
87. Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, ACCOMPLISH Trial Investigators, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008, 359(23):2417-2428.
88. Bakris GL, Sarafidis PA, Weir MR, Dahlöf B, Pitt B, Jamerson K, ACCOMPLISH Trial investigators, et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 2010, 375(9721):1173-1181.
89. Rahman M, Ford CE, Cutler JA, Davis BR, Piller LB, Whelton PK Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering treatment to Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated GFR. Clin J Am Soc Nephrol 2012, 7(6):989-1002.
90. Hermida RC, Ayala DE, Mojón A, Fernández JR Bedtime dosing of antihypertensive medications reduces cardiovascular risk in CKD. J Am Soc Nephrol 2011, 22(12):2313-2321.
91. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005, 353(3):238-348.
92. Fellstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, et al. Statin therapy offered no cardiovascular benefit to patients undergoing hemodialysis. N Engl J Med 2009, 360(14):1395-1407.
93. Baigent C, Landray M, Emberson J, Wheeler DC, Tomson C, SHARP Investigators, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimide in patient with chronic kidney disease (Study of Heart and Renal Protection): a randomized placebo-controlled trial. Lancet 2011, 377(9784):2181-2192.
94. Stack AG, Murthy BV Cigarette use and cardiovascular risk in chronic kidney disease: an unappreciated modifiable lifestyle risk factor. Semin Dial 2010, 23(3):298-305.
95. Antithrombotic Trialists' (ATT) Collaboration, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009, 373(9678):1849-1860.
96. Palmer SC, Di Micco L, Razavian M, Craig JC, Perkovic V, Pellegrini F, et al. Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med 2012, 156(6):445-459.
97. Brown A, Reynolds LR, Bruemmer D Intensive glycemic control and cardiovascular disease: an update. Nat Rev Cardiol 2010, 7(7):369-375.
98. ACCORD Study Group, Gerstein HC, Miller ME, Genuth S, Ismail-Beigi F, Buse JB, et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 2011, 364(9):818-828.
99. The ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358(24):2560-2572.
100. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006, 355(20):2071-2084.
101. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006, 355(20):2085-2098.
102. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009, 361(21):2019-2032.
103. Fishbane S, Schiller B, Locatelli F, Covic AC, Provenzano R, Wiecek A, EMERALD Study Groups, et al. Peginesatide in patients with anemia undergoing hemodialysis. N Engl J Med 2013, 368(4):307-319.
104. Macdougall IC, Provenzano R, Sharma A, Spinowitz BS, Schmidt RJ, Pergola PE, et al. Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis. N Engl J Med 2013, 368(4):320-332.
105. Kuo CF, See LC, Yu KH, Chou IJ, Chiou MJ, Luo SF Significance of serum uric acid levels on the risk of all-cause and cardiovascular mortality. Rheumatology (Oxford) 2013, 52(1):127-134.
106. Dhaun N, Melville V, Blackwell S, Talwar DK, Johnston NR, Goddard J, et al. Endothelin-A receptor antagonism modifies cardiovascular risk factors in CKD. J Am Soc Nephrol 2013, 24(1):31-36.
107. Jardine MJ, Kang A, Zoungas S, Navaneethan SD, Ninomiya T, Nigwekar SU, et al. The effect of folic acid based homocysteine lowering on cardiovascular events in people with kidney disease: systematic review and meta-analysis. BMJ 2012, 344:e3533.
108. The EVOLVE Trial Investigators, Chertow GM, Block GA, Correa-Rotter R, Drüeke TB, Floege J, et al. Effect of cinacalcet on cardiovascular disease in patients undergoing hemodialysis. New Engl J Med 2012, 367(26):2482-2494.
109. Mann JF, Lonn EM, Yi Q, Hoogwerf BJ, Pogue J, Bosch J, et al. Effects of vitamin E on cardiovascular outcomes in people with mild-to-moderate renal insufficiency: results of the HOPE study. Kidney Int 2004, 65(4):1375-1380.
110. Jun M, Venkataraman V, Razavian M, et al. Antioxidants for chronic kidney disease. Cochrane Database Syst Rev 2012, 10:CD008176.
111. Rakhit DJ, Marwick TH, Armstrong KA, Johnson DW, Leano R, Isbel NM Effect of aggressive risk factor modification on cardiac events and myocardial ischaemia in patients with chronic kidney disease. Heart 2006, 92(10):1402-1408.
112. Barrett BJ, Garg AX, Goeree R, Levin A, Molzahn A, Rigatto C, et al. A nurse-coordinated model of care versus usual care for stage 3/4 chronic kidney disease in the community: a randomized controlled trial. Clin J Am Soc Nephrol 2011, 6(6):1241-1247.
113. van Zuilen AD, Blankestijn PJ, van Buren M, ten Dam MA, Kaasjager KA, Ligtenberg G, et al. Nurse practitioners improve quality of care in chronic kidney disease: two-year results of a randomised study. Neth J Med 2011, 69(11):517-526.
114. Gaede P, Lund-Andersen H, Parving HH, Pedersen O Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008, 358(6):580-591.
115. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, American College of Cardiology Foundation, American Heart Association, et al. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 2009, 53:e1-e90.
116. Anand IS, Bishu K, Rector TS, Ishani A, Kuskowski MA, Cohn JN, et al. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure. Circulation 2009, 120(16):1577-1584.
117. Castagno D, Jhund PS, McMurray JJ, Lewsey JD, Erdmann E, Zannad F, et al. Improved survival with bisoprolol in patients with heart failure and renal impairment: an analysis of the cardiac insufficiency bisoprolol study II (CIBIS-II) trial. Eur J Heart Fail 2010, 12(6):607-616.
118. Wali RK, Iyengar M, Beck GJ, Chartyan DM, Chonchol M, Lukas MA, et al. Efficacy and safety of carvedilol in treatment of heart failure with chronic kidney disease: a meta-analysis of randomized trials. Circ Heart Fail 2011, 4(1):18-26.
119. Ghali JK, Wikstrand J, Van Veldhuisen DJ, Fagerberg B, Goldstein S, Hjalmarson A, et al. The influence of renal function on clinical outcome and response to beta-blockade in systolic heart failure: insights from Metoprolol CR/XL Randomized Intervention Trial in Chronic HF (MERIT-HF). J Card Fail 2009, 15(4):310-318.
120. Damman K, Voors AA, Hillege HL, Navis G, Lechat P, van Veldhuisen DJ, et al. Congestion in chronic systolic heart failure is related to renal dysfunction and increased mortality. Eur J Heart Fail 2010, 12(9):974-982.
121. Bart BA, Goldsmith SR, Lee KL, Givertz MM, O'Connor CM, Bull DA, et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med 2012, 367(24):2296-2304.
122. Taheri S, Mortazavi M, Pourmoghadas A, Seyrafian Shiva, Alipour Zeynab, Shirin Karimi A prospective double-blind randomized placebo-controlled clinical trial to evaluate the safety and efficacy of spironolactone in patients with advanced congestive heart failure on continuous ambulatory peritoneal dialysis. Saudi J Kidney Dis Transpl 2012, 23(3):507-512.
123. Hart RG, Pearce LA, Asinger RW, Herzog CA Warfarin in atrial fibrillation patients with moderate chronic kidney disease. Clin J Am Soc Nephrol 2011, 6(11):2599-2604.
124. Connolly SJ, Ezekowitz MD, Yusuf S, Herzog CA, RE-LY Steering Committee and Investigators Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009, 361:1139-1151.
125. Manske CL, Wang Y, Rector T, Wilson RF, White CW Coronary revascularisation in insulin-dependent diabetic patients with chronic renal failure. Lancet 1992, 340(8826):998-1002.
126. Chang TI, Shilane D, Kazi DS, Montez-Rath ME, Hlatky MA, Winkelmayer WC Multivessel coronary artery bypass grafting versus percutaneous coronary intervention in ESRD. J Am Soc Nephrol 2012, 23(12):2042-2049.
127. Ashrith G, Lee VV, Elayda MA, Reul RM, Wilson JM Short- and long-term outcomes of coronary artery bypass grafting or drug-eluting stent implantation for multivessel coronary artery disease in patients with chronic kidney disease. Am J Cardiol 2010, 106(3):348-353.
128. Farkouh ME, Domanski M, Sleeper LA, Siami FS, Dangas G, Mack M, et al. Strategies for multivessel revascularization in patients with diabetes. N Engl J Med 2012, 367(25):2375-2384.
129. Rao V, Weisel RD, Buth KJ, Cohen G, Borger MA, Shiono N, et al. Coronary artery bypass grafting in patients with non- dialysis-dependent renal insufficiency. Circulation 1997, 96(9 Suppl). II-38-43; discussion II-44-5.
130. Hedley AJ, Roberts MA, Hayward PA, Shaw M, Matalanis G, Buxton BF, et al. Impact of chronic kidney disease on patient outcome following cardiac surgery. Heart Lung Circ 2010, 19(8):453-459.
131. Appleby CE, Ivanov J, Lavi S, Mackie K, Horlick EM, Ing D, et al. The adverse long-term impact of renal impairment in patients undergoing percutaneous coronary intervention in the drug-eluting stent era. Circ Cardiovasc Interv 2009, 2(4):309-316.
132. Kersting S, Grumann T, Hummel J, Hauschke D, Bode C, Hehrlein C Impact of chronic kidney disease on long-term clinical outcomes after percutaneous coronary intervention with drug-eluting or bare-metal stents. Crit Pathw Cardiol 2012, 11(3):152-159.
133. Herzog CA, Asinger RW, Berger AK, Charytan DM, Díez J, Hart RG, et al. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2011, 80(6):572-586.
134. Abbas AE, Goodman LM, Timmis R, Boura J Predictors of poor outcome in female patients undergoing endovascular intervention. J Interv Cardiol 2010, 23(4):401-410.
135. Jaar BG, Astor BC, Berns JS, Powe NR Predictors of amputation and survival following lower extremity revascularization in hemodialysis patients. Kidney Int 2004, 65(2):613-620.
136. Mathew A, Eliasziw M, Devereaux PJ, Merino JG, Barnett HJ, Garg AX, et al. Carotid endarterectomy benefits patients with CKD and symptomatic high-grade stenosis. J Am Soc Nephrol 2010, 21(1):145-152.